According to studies [6,7,8], humanized anti-HER2 antibodies like trastuzumab and pertuzumab, as well as selective estrogen receptor modulators (SERMs) like tamoxifen and toremifene, represent the gold standard for treating patients with breast cancers that are ER and HER2 positive, respectively. The gene discussed is ESR1; the disease is breast cancer.